Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 16:13:1087260.
doi: 10.3389/fendo.2022.1087260. eCollection 2022.

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)

Li Rong  1 , Junyan Zou  2   3 , Wei Ran  3 , Xiaohong Qi  4 , Yaokai Chen  3 , Hongjuan Cui  2 , Jinjun Guo  1
Affiliations
Review

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)

Li Rong et al. Front Endocrinol (Lausanne). .

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. In order to more accurately reflect its pathogenesis, an international consensus renamed NAFLD in 2020 as metabolic (dysfunction) associated with fatty liver disease (MAFLD). The changes in diet and lifestyle are recognized the non-drug treatment strategies; however, due to the complex pathogenesis of NAFLD, the current drug therapies are mainly focused on its pathogenic factors, key links of pathogenesis, and related metabolic disorders as targets. There is still a lack of specific drugs. In clinical studies, the common NAFLD treatments include the regulation of glucose and lipid metabolism to protect the liver and anti-inflammation. The NAFLD treatments based on the enterohepatic axis, targeting gut microbiota, are gradually emerging, and various new metabolism-regulating drugs are also under clinical development. Therefore, this review article has comprehensively discussed the research advancements in NAFLD treatment in recent years.

Keywords: diet; exercise; medical treatment; non-alcoholic steatohepatitis; nonalcoholic fatty liver disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (Nafld). Metabolism (2016) 65(8):1038–48. doi: 10.1016/j.metabol.2015.12.012 - DOI - PubMed
    1. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) . Easl-Easd-Easo clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol (2016) 64(6):1388–402. doi: 10.1016/j.jhep.2015.11.004 - DOI - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. Hepatology (2018) 67(1):328–57. doi: 10.1002/hep.29367 - DOI - PubMed
    1. Glen J, Floros L, Day C, Pryke R. Non-alcoholic fatty liver disease (Nafld): Summary of nice guidance. BMJ (Clinical Res ed (2016) 354:i4428. doi: 10.1136/bmj.i4428 - DOI - PubMed
    1. Risi R, Tozzi R, Watanabe M. Beyond weight loss in nonalcoholic fatty liver disease: The role of carbohydrate restriction. Curr Opin Clin Nutr Metab Care (2021) 24(4):349–53. doi: 10.1097/mco.0000000000000762 - DOI - PubMed

Publication types

MeSH terms